Major Win for Childhood Cancer Advocacy: UN Adopts GICC Target
Marty Makary: FDA Rejection Letters are Now Public
FDA Approves RYBREVANT FASPRO as the First Subcutaneous Amivantamab Option for EGFR-Mutated NSCLC
David Steensma: Ajax Therapeutics Receives Orphan Drug Designation by FDA for AJ1-11095 for the Treatment of Myelofibrosis
Tom Powles: Another Step Towards Curing Bladder Cancer
ASCO Joins One Voice Against Cancer’s Day of Action Urging Congress to Pass a Final Labor-HHS Funding Bill
Maryam Lustberg: From Phase 2 Promise to Phase 3 Proof in Neuropathy Prevention
FDA Awarded a National Priority Voucher to Teclistamab with Daratumumab for R/R Multiple Myeloma
